Gemeinschaftsklinikum Mittelrhein gGmbH — Clinical Trial Site

25 Registered trials

11 Currently recruiting

Organisation

Gemeinschaftsklinikum Mittelrhein gGmbH

Location

Koblenz, Germany

Identifier

ORG-100029347

Address

Koblenzer Str 115-155, 56073, Germany

Departments

Gemeinschaftsklinikum Mittelrhein gGmbH
Gemeinschaftsklinikum Mittelrhein gGmbH Ev. Stift St. Martin Klinik für Innere Med, Studienzentrum
Gesundheitszentrum Evang. Stift St. Martin Zentrum für Innere Medizin
Hämatologie/Onkologie
Hämatologie/Onkologie/Palliativmedizin
Hematology and Oncology
Innere Medizin
Innere Medizin - Hämatologie/Onkologie, Palliativmedizin
Innere Medizin — Hämatologie/Onkologie, Palliativmedizin
Innere Medizin, Hämatologie, Onkologie, Palliativmedizin
Innere Medizin, Hämatologie/Onkologie
Klinik für Innere Medizin
Klinik für Kinder und Jugendmedizin
Klinik für Kinder- und Jugendmedizin Pädiatrische Hämatologie und Onkologie
Klinik für Kinderheilkunde und Jugendmedizin
Päd. Hämatologie und Onkologie
Pädiatrische Hämatologie und Onkologie
Paedriatrics, Department of Oncology and Hematology
Pediatric hematology and oncology

Clinical trials at this site (25)

Search interface

SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Medulloblastoma 10
Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending

2025-523990-40-00 Newly diagnosed Multiple Myeloma in patients eligible f 5
A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-c… Recruiting

2023-507402-13-00 Multiple myeloma 5 2024-04-03
A clinical study of zilovertamab vedotin with R-CHP treatment in people with diffuse large B-cell lymphoma (MK-2140-011) Recruiting

2024-515526-89-00 Diffuse Large B-Cell Lymphoma (DLBCL) 4 2025-05-16
Efficacy of Venetoclax in combination with Rituximab in Waldenström’s Macroglobulinemia Recruiting

2022-500574-34-00 Waldenström’s Macroglobulinemia 4 2025-03-21
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Age-adjusted high-dose chemotherapy followed by autologous stem cell transplantation or conventional chemotherapy with R-MP as first-line tr… Recruiting

2024-512320-11-00 Primary diffuse large B-cell lymphoma of the central ne 5 2023-08-09
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Mantle Cell Lymphoma 4 2023-05-15
SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting

2024-510578-25-00 Histologically proven high-risk medulloblastoma, with a 5 2021-11-05
Midostaurin + Gemtuzumab Ozogamicin combination in first-line standard therapy for acute myeloid leukemia (MOSAIC) Recruiting

2024-514014-13-00 female and male adult patients with acute myeloid leuke 9 2020-09-02
LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting

2023-508101-24-00 Lymphoblastic lymphoma 5 2019-08-01
SIOP Ependymoma II: An International Clinical Program for the diagnosis and treatment of children, adolescents and young adults with ependym… Recruiting

2024-512222-28-00 Newly diagnosed with an intracranial or spinal ependymo 10 2015-06-02
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma Ended

2022-500571-32-00 Early-Stage Unfavorable Classical Hodgkin Lymphoma 4 2024-05-15
Optimizing MATRix, a combination of Methotrexate, Ara-C, Thiotepa and Rituximab given as an induction therapy, de-escalated in duration and … Ended

2024-514473-21-00 Primary diffuse large B-cell lymphoma (DLBCL) of the ce 5 2021-06-21
Comparison of therapies before stem cell transplantation in patients with higher risk MDS and oligoblastic AML Ended

2024-515375-35-00 Untreated patients with higher risk MDS and oligoblasti 4 2019-08-26
Elotuzumab (E) in Combination with Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) versus KRd prior to and following Autologous Stem Cel… Ended

2024-515783-31-00 Newly Diagnosed Multiple Myeloma 5 2018-08-24
AIEOP-BFM ALL 2017 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia Ended

2023-509856-32-00 acute lymphoblastic leukemia in children and adolescent 5 2018-07-15
International Study for Treatment of High Risk Childhood Relapsed ALL 2010 - A randomized Phase II Study Conducted by the Resistant Disease … Ended

2024-513070-21-00 Relapsed Acute Lymphoblastic Leukemia (ALL) 4 2018-02-15
International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended

2024-515499-12-00 Acute lymphoblastic leukemia 5 2017-10-02
B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and… Ended

2023-505509-18-00 mature aggressive B-cell lymphoma and leukemia in child 5 2017-07-12
International multicenter, open-label clinical trial for the treatment of acute myeloid leukemia in children and adolescents Halted

2022-500783-35-00 Acute Myeloid Leukemia 5 2022-12-06
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25